Equity volatility picked up after the bell as corporate reports and filings reshaped expectations across several industries. The most pronounced moves came from a defense contractor and an AI infrastructure play that drew strong investor interest, while a semiconductor components supplier and a customer-experience technology firm saw heavy selling following capital-raising and guidance revisions. A neuroscience drugmaker experienced a regulatory delay that pushed its review timeline into late December.
AeroVironment (AVAV)
AeroVironment shares climbed sharply, rising 19% in after-hours trading after the company posted fourth-quarter results that beat analyst forecasts. On an earnings-per-share basis, the company reported $1.84, which was $0.36 ahead of expectations. Revenue for the quarter reached $641.6 million versus a consensus figure of $557.37 million. Investors concentrated on the top-line strength despite management’s mixed fiscal 2027 outlook - the company projected EPS of $3.02 to $3.34, below the Wall Street estimate of $3.79. Management also provided a strong revenue outlook, indicating potential sales of up to $2.23 billion, a signal of continued demand for its uncrewed aircraft systems.
Praxis Precision Medicines (PRAX)
Shares of Praxis fell about 7% after the Food and Drug Administration extended its review period for relutrigine by three months. The extension moves the Prescription Drug User Fee Act target action date to December 27, 2026. The FDA classified Praxis’s supplemental submission of additional sensitivity analyses as a "major amendment," which triggered the delay. Importantly, the agency did not request new clinical trials and did not cite safety concerns, leaving the application active and under review.
Vishay Intertechnology (VSH)
Vishay’s shares dropped roughly 10% after the company disclosed an underwritten public offering of $750 million in common stock, with underwriters granted a 30-day option to buy an additional $112.5 million. The announcement of sizeable equity issuance raised concerns among investors about dilution for existing shareholders and prompted significant selling in the electronic components manufacturer’s shares.
Concentrix Corporation (CNXC)
Concentrix tumbled approximately 26% following a fiscal second-quarter report that narrowly missed both earnings and revenue expectations. The greater impact, however, came from management’s revised outlook: full-year 2026 EPS was lowered to a range of $10.83 to $11.18, well under the consensus estimate of $11.71. The company cited pressures consistent with slowing enterprise spending and pricing headwinds, which weighed on investor sentiment for the customer-experience technology firm.
SharonAI Holdings (SHAZ)
SharonAI shares surged 78% after a regulatory filing revealed a substantial institutional position. The filing showed Situational Awareness LP holding nearly 1.7 million shares of Class A common stock, together with pre-funded warrants that could represent an additional 6.37 million shares. That disclosure of concentrated insider/institutional exposure spurred intense retail buying in the high-performance computing and AI infrastructure-focused company.
Taken together, the after-hours moves reflect a market environment in which company-specific drivers - from earnings beats and guidance updates to regulatory classifications and capital raises - can produce large swings in individual securities across defense, biotechnology, electronic components, customer-experience technology and AI infrastructure sectors.